MyoKardia Inc (MYOK) - Financial and Strategic SWOT Analysis Review

  • ID: 4278939
  • SWOT Analysis
  • 43 pages
  • GlobalData
  • MyoKardia Inc
1 of 5

FEATURED COMPANIES

  • Ampio Pharmaceuticals Inc
  • Ardelyx Inc
  • aTyr Pharma Inc
  • CymaBay Therapeutics Inc
  • MORE
MyoKardia Inc (MYOK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

MyoKardia Inc (MyoKardia) is a clinical stage biopharmaceutical company. It is a precision medicine provider that develops therapies for rare cardiovascular diseases. The company's pipeline products comprise MYK-461 is an orally administered small molecule which is designed to reduce left ventricular contractility by allosterically modulating the function of cardiac myosin and MYK-491 is used treat dilated cardiomyopathy. It provides HCM-2 and LUS-1 to counteract muscle disruption resulting in impaired relaxation of the heart and other applications. The company works in collaboration with other drug developers. MyoKardia is headquartered in South San Francisco, California, the US.

MyoKardia Inc Key Recent Developments

Aug 07,2017: MyoKardia Reports Second Quarter 2017 Financial Results and Operational Progress
Apr 18,2017: MyoKardia Appoints David Meeker, M.D., to Board of Directors
Mar 17,2017: MyoKardia Appoints Kim Popovits and Wendy Yarno to Board of Directors
Mar 13,2017: MyoKardia Reports Fourth Quarter and Full Year 2016 Financial Results and Operational Progress
Feb 01,2017: MyoKardia Announces Appointment of June Lee, M.D., as Chief Operating Officer and Radhika Tripuraneni, M.D., as Vice President, Medical Affairs

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Ampio Pharmaceuticals Inc
  • Ardelyx Inc
  • aTyr Pharma Inc
  • CymaBay Therapeutics Inc
  • MORE
Section 1 - About the Company
  • MyoKardia Inc - Key Facts
  • MyoKardia Inc - Key Employees
  • MyoKardia Inc - Major Products and Services
  • MyoKardia Inc - History
  • MyoKardia Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • MyoKardia Inc - Business Description
  • MyoKardia Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • MyoKardia Inc - Strengths
  • MyoKardia Inc - Weaknesses
  • MyoKardia Inc - Opportunities
  • MyoKardia Inc - Threats
  • MyoKardia Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
  • MyoKardia Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 07, 2017: MyoKardia Reports Second Quarter 2017 Financial Results and Operational Progress
  • Apr 18, 2017: MyoKardia Appoints David Meeker, M.D., to Board of Directors
  • Mar 17, 2017: MyoKardia Appoints Kim Popovits and Wendy Yarno to Board of Directors
  • Mar 13, 2017: MyoKardia Reports Fourth Quarter and Full Year 2016 Financial Results and Operational Progress
  • Feb 01, 2017: MyoKardia Announces Appointment of June Lee, M.D., as Chief Operating Officer and Radhika Tripuraneni, M.D., as Vice President, Medical Affairs
  • Dec 01, 2016: MyoKardia Announces Appointment of Marc Semigran, M.D., as Chief Medical Officer
  • Nov 07, 2016: MyoKardia Reports Progress on Clinical Programs and Third Quarter 2016 Financial Results
  • Aug 09, 2016: MyoKardia Reports Second Quarter 2016 Financial Results and Continued Progress on Clinical Programs
  • May 12, 2016: MyoKardia Reports First Quarter 2016 Financial Results and Operational Progress
  • Apr 13, 2016: MyoKardia Names Mary Cranston to Board of Directors
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • MyoKardia Inc, Key Facts
  • MyoKardia Inc, Key Employees
  • MyoKardia Inc, Major Products and Services
  • MyoKardia Inc, History
  • MyoKardia Inc, Subsidiaries
  • MyoKardia Inc, Key Competitors
  • MyoKardia Inc, Ratios based on current share price
  • MyoKardia Inc, Annual Ratios
  • MyoKardia Inc, Annual Ratios (Cont...1)
  • MyoKardia Inc, Interim Ratios
  • MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
  • MyoKardia Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • MyoKardia Inc, Performance Chart (2013 - 2016)
  • MyoKardia Inc, Ratio Charts
  • MyoKardia Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
  • MyoKardia Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • CymaBay Therapeutics Inc
  • aTyr Pharma Inc
  • Arrowhead Pharmaceuticals Inc
  • Ardelyx Inc
  • Ampio Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll